Eye injection study aims to control diabetic vision loss
NCT ID NCT05959304
Summary
This study is monitoring the safety and effectiveness of brolucizumab, an eye injection, for diabetic macular edema (DME) in a real-world setting. It involves 63 adult patients in India who have vision problems due to DME and are already scheduled to receive this treatment. Researchers will track patients' vision and eye health over 40 weeks to see how well the injections work and what side effects occur.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380052, India
-
Novartis Investigative Site
Bangalore, Karnataka, 560 010, India
-
Novartis Investigative Site
Kochi, Kerala, 682 026, India
-
Novartis Investigative Site
Chennai, Tamil Nadu, 600045, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700 073, India
-
Novartis Investigative Site
Coimbatore, 641002, India
-
Novartis Investigative Site
Kolkata, 700120, India
-
Novartis Investigative Site
New Delhi, 110029, India
Conditions
Explore the condition pages connected to this study.